https://economymiddleeast.com/ :Event will connect fast-growing healthcare sectors with investors, policymakers, researchers and global industry leaders 

World Health Expo is widening its commercial and scientific focus for its 2027 edition in Dubai, bringing pharmaceuticals, biotechnology, longevity and wellness further into an event expected to attract more than 90,000 attendees from around the world.

The new Pharma, Biotech, Longevity and Wellness industry sectors are designed to showcase the rapid expansion of markets collectively worth trillions of dollars as healthcare investment increasingly moves beyond conventional care toward advanced therapeutics, prevention, precision medicine and healthy aging. 

WHX 2027 will take place from January 25 to 28 across Dubai Exhibition Centre at Expo City Dubai and Dubai World Trade Centre, providing a platform for investment discussions, commercial partnerships and collaboration around the technologies and business models shaping healthcare. 

The expansion comes as healthcare spending continues to rise across the GCC. PwC Middle East estimates regional healthcare expenditure will reach $159 billion by 2029, while more than 160 healthcare projects valued at approximately $53.2 billion are already underway across hospitals, specialty centers and supporting infrastructure. 

Growth markets expand
The longevity economy is emerging as one of the largest of those opportunities. Bank of Singapore estimates the global market will expand from around $3 trillion in 2025 to $5.4 trillion by 2034, representing annual growth of approximately 6 to 7 percent. Healthcare is expected to capture a significant share of that expanding economy as longer lifespans increase demand for prevention, diagnostics, therapeutics and other services supporting healthy aging.

The UAE is developing its own position in that market. The country’s longevity sector is estimated to reach $32 billion in 2026, up from approximately $19 billion in 2020, according to figures cited by the Department of Health – Abu Dhabi. 

Pharmaceuticals represent another major growth area. IQVIA estimates that the global prescription medicine market reached about $1.7 trillion at list prices in 2025, increasing 10 percent year over year. 

Growth was even faster across the Middle East and Africa, where pharmaceutical sales increased 18 percent, the strongest growth among the regions analyzed by IQVIA. The research group linked the expansion to factors including improving access, policy reforms and rising demand. 

Solenne Singer, Senior Vice President – Healthcare at inD, said healthcare investment is rapidly extending into pharmaceuticals, biotechnology, longevity and wellness, reflecting a fundamental change in where the industry sees future value. 

Investment meets innovation
Singer said bringing together organizations that develop, finance, regulate and implement next-generation healthcare enables WHX to create a platform for commercially important discussions.

She added that highlighting opportunities in pharma and biotech alongside the expanding longevity and wellness industries can connect these sectors with the wider healthcare ecosystem and international investors increasingly focused on opportunities across the GCC. 

One of the central shifts behind the expansion is healthcare’s growing emphasis on preventing disease and extending healthspan — the number of years people spend in good health — rather than focusing exclusively on treating illness after it develops.

WHX’s Longevity and Wellness sectors will provide a dedicated platform for organizations working across prevention, healthy aging, precision health and wellness. The new zones will be based at Dubai World Trade Centre alongside laboratory, medical equipment and other healthcare sectors.

The Healthspan Stage will anchor the longevity and wellness content across the four-day event. WHX says the stage will bring together innovators, practitioners and technologies involved in healthy aging, biotechnology and life sciences. 

The wider longevity and wellness program will convene government leaders, healthcare providers, medical societies and researchers to examine preventive and metabolic health, aging science, wearable and diagnostic data, and ways to move longevity into an accessible and evidence-based part of mainstream healthcare.

Dubai longevity push
The expansion follows Dubai’s establishment of the Dubai Longevity Authority in June 2026, creating a dedicated regulator and development body for longevity, wellness and advanced healthcare.

The authority was established under Law No. 17 of 2026 with a mandate covering the longevity value chain, including research and development, clinical trials, manufacturing, delivery and patient clinics. It is intended to provide a science-driven regulatory framework while encouraging investment, technology transfer and specialized talent. 

Its creation supports Dubai’s ambitions to rank among the world’s top three cities for quality of life and achieve a leading position in healthy life expectancy under the Dubai Economic Agenda, D33, and Dubai Social Agenda 33. 

The authority’s emphasis on life sciences, biotechnology, advanced therapies, preventive interventions and regulated longevity products closely aligns with the four sectors receiving a larger platform at WHX 2027. 

The pharmaceutical component of WHX will meanwhile bring together drugmakers, biotechnology innovators, manufacturers, researchers, investors and healthcare organizations as global and regional demand continues to increase.

Dubai’s broader investment performance provides a strong backdrop. The emirate ranked No. 1 globally for greenfield FDI projects in the life sciences cluster in 2025, according to Financial Times fDi Markets data published by Dubai’s Department of Economy and Tourism.

Life sciences expand
Dubai also ranked first globally across several other strategic clusters in 2025 while attracting 1,253 announced greenfield FDI projects overall, up 10.5 percent from 2024. Total announced greenfield FDI capital reached $8.83 billion, or AED32.43 billion.

The emirate’s research and commercialization infrastructure includes Dubai Science Park, which marked its 20th anniversary in 2026. The TECOM Group district is home to more than 90 laboratories supporting scientific research and more than 6,500 professionals working across life, energy and environmental sciences. 

The new Biotech sector at WHX will showcase companies, products and technologies contributing to growth in biotechnology across regional and international markets.

Its content will include biotechnology and life-sciences discussions on the Healthspan Stage, bringing pharmaceutical executives, biotechnology companies, regulators, researchers and investors together to examine how scientific discoveries can be transformed into medicines and commercially viable healthcare solutions. 

The discussions will span genomics and precision medicine, clinical trials, biomanufacturing and patient access, reflecting the increasingly interconnected pathway between scientific research, regulation, production and healthcare delivery.

The regional biotechnology investment story extends beyond the UAE. Saudi Arabia’s National Biotechnology Strategy aims to make the Kingdom the leading biotechnology hub in the Middle East and North Africa by 2030 and a global leader by 2040.

Saudi biotech ambitions
Saudi Arabia is targeting a biotechnology contribution exceeding $34.6 billion to non-oil GDP by 2040, equivalent to around 3 percent of non-oil GDP. The strategy also targets 11,000 high-quality jobs by 2030 and 55,000 by 2040.

Its four main strategic areas include vaccines, biomanufacturing and localization, genomics and plant optimization, positioning biotechnology as both a healthcare industry and a broader economic-diversification opportunity.

WHX’s expanded sector structure is intended to connect those regional ambitions with international businesses, capital and research organizations.

Another addition to the 2027 show floor will be the Connections Programme, a week-long networking initiative operating through two dedicated Connections Lounges.

Rather than relying solely on one-to-one matchmaking, the program will use curated, theme-led group sessions bringing together relevant healthcare communities according to their roles, markets and commercial priorities. More than 20 sessions are planned across the week. 

Sessions under development include exchanges connecting biotech innovators with pharmaceutical partners, investors, hospitals, clinical research centers and policymakers, as well as networking focused on preventive health, wellness and longevity diagnostics.

Global event expands
WHX 2027 is expected to attract more than 90,000 unique attendees, over 4,200 exhibitors and representatives from more than 195 countries, with approximately 235,000 professional visits anticipated across the four-day event.

The exhibition forms part of World Healthcare Week alongside WHX Tech and WHX Leaders, bringing healthcare trade, digital health, technology, investment and senior leadership programming together in Dubai.

For one week in January 2027, the three events will operate across Dubai Exhibition Centre and Dubai World Trade Centre, allowing different areas of the healthcare industry to gather in the same city and connect commercial activity with technology and policy discussions.

The two-venue structure also separates different areas of the healthcare ecosystem. Dubai Exhibition Centre will host sectors including medical equipment, imaging, diagnostics, infrastructure and healthcare services, while Dubai World Trade Centre will house laboratory medicine alongside the new Longevity and Pharma & Biotech zones and the Healthspan Stage.

The 2027 edition therefore represents a broader version of WHX’s healthcare platform, placing a greater emphasis on industries where scientific development, consumer demand and healthcare investment are increasingly converging.

WHX broadens its scope
The latest announcement builds on a transformation that had already begun before the 2027 edition. WHX, formerly Arab Health, moved to Dubai Exhibition Centre for the first time in February 2026 after more than five decades associated with Dubai World Trade Centre. 

The relocation followed a strategic partnership between World Health Expo and Expo City Dubai aimed at increasing event capacity and creating additional opportunities for international collaboration. The 2026 move provided an additional 11,343 square meters, taking available event space to 74,402 square meters. 

Biotechnology was also gaining a larger platform before the current announcement. In December 2025, WHX announced that its 2026 event would debut a specialized Biotech & Life Sciences Zone as the global biotechnology market was projected to exceed $4 trillion by 2035. The organizer also cited expectations for the GCC biotechnology market to reach $2.6 billion by 2028.

The 2027 strategy therefore builds on that earlier biotechnology push rather than introducing biotechnology to WHX for the first time, broadening the sector’s position within a unified event that now includes expanded pharma, longevity and wellness offerings.

Regional healthcare investment
Dubai’s parallel development of its life-sciences infrastructure gives the event expansion a wider economic context. Dubai Science Park has continued adding research, laboratory, storage and logistics capacity, with companies including major international pharmaceutical and healthcare groups operating within its ecosystem. Its expansion project was designed to increase storage and logistics capacity by 147 percent to meet growing demand from science and R&D businesses.

The establishment of the Dubai Longevity Authority has added a regulatory layer to that ecosystem, covering activities from experimental research and clinical trials through manufacturing and patient delivery.

Abu Dhabi has also expanded its longevity and precision-medicine agenda. In 2025, the Department of Health – Abu Dhabi launched a Declaration on Longevity and Precision Medicine aimed at accelerating personalized care, AI-enabled diagnostics and longevity research. The department noted that the global gap between lifespan and healthy lifespan remains close to a decade.